SK155997A3 - Use of ribavirin and interferon alpha for the treatment of hepatitis c - Google Patents

Use of ribavirin and interferon alpha for the treatment of hepatitis c Download PDF

Info

Publication number: SK155997A3
Authority: SK; Slovakia
Prior art keywords: ribavirin; interferon alpha; hepatitis; interferon; amount
Prior art date: 1995-05-19

Application number

SK1559-97A

Other languages

English (en)

Slovak (sk)

Inventor

Janice K Albrecht

Paul C Grint

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-05-19

Filing date

1996-05-15

Publication date

1998-10-07

1996-05-15 Application filed by Schering Corp filed Critical Schering Corp

1998-10-07 Publication of SK155997A3 publication Critical patent/SK155997A3/sk

Links

IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 24
229960000329 ribavirin Drugs 0.000 title claims abstract description 24
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 24
108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 22
102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 22
208000006454 hepatitis Diseases 0.000 title description 2
231100000283 hepatitis Toxicity 0.000 title 1
230000001684 chronic effect Effects 0.000 claims description 12
208000037319 Hepatitis infectious Diseases 0.000 claims description 10
208000005252 hepatitis A Diseases 0.000 claims description 10
239000003814 drug Substances 0.000 claims description 3
102100040018 Interferon alpha-2 Human genes 0.000 claims description 2
108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
206010062237 Renal impairment Diseases 0.000 claims 2
208000020832 chronic kidney disease Diseases 0.000 claims 1
230000003442 weekly effect Effects 0.000 claims 1
230000000694 effects Effects 0.000 abstract description 15
208000020403 chronic hepatitis C virus infection Diseases 0.000 abstract description 3
238000000034 method Methods 0.000 abstract description 2
102000014150 Interferons Human genes 0.000 description 12
108010050904 Interferons Proteins 0.000 description 12
238000002560 therapeutic procedure Methods 0.000 description 11
229940079322 interferon Drugs 0.000 description 9
238000009097 single-agent therapy Methods 0.000 description 9
208000024891 symptom Diseases 0.000 description 7
238000002648 combination therapy Methods 0.000 description 6
108010078049 Interferon alpha-2 Proteins 0.000 description 5
239000000203 mixture Substances 0.000 description 5
208000005176 Hepatitis C Diseases 0.000 description 4
238000009472 formulation Methods 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
206010022004 Influenza like illness Diseases 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002458 infectious effect Effects 0.000 description 2
229960003507 interferon alfa-2b Drugs 0.000 description 2
208000019423 liver disease Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 2
206010008909 Chronic Hepatitis Diseases 0.000 description 1
208000006154 Chronic hepatitis C Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
206010019837 Hepatocellular injury Diseases 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
208000000112 Myalgia Diseases 0.000 description 1
206010037660 Pyrexia Diseases 0.000 description 1
102000007397 Species specific proteins Human genes 0.000 description 1
108020005719 Species specific proteins Proteins 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
208000007475 hemolytic anemia Diseases 0.000 description 1
208000010710 hepatitis C virus infection Diseases 0.000 description 1
206010073071 hepatocellular carcinoma Diseases 0.000 description 1
231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
230000028993 immune response Effects 0.000 description 1
108010055511 interferon alfa-2c Proteins 0.000 description 1
108010006088 interferon alfa-n1 Proteins 0.000 description 1
229960001388 interferon-beta Drugs 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000013465 muscle pain Diseases 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
-1 transdermal Substances 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK1559-97A 1995-05-19 1996-05-15 Use of ribavirin and interferon alpha for the treatment of hepatitis c SK155997A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/444,584 US6387365B1 (en)	1995-05-19	1995-05-19	Combination therapy for chronic hepatitis C infection
PCT/US1996/006552 WO1996036351A1 (en)	1995-05-19	1996-05-15	Use of ribavirin and interferon alpha for the treatment of hepatitis c

Publications (1)

Publication Number	Publication Date
SK155997A3 true SK155997A3 (en)	1998-10-07

Family

ID=23765515

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1559-97A SK155997A3 (en)	1995-05-19	1996-05-15	Use of ribavirin and interferon alpha for the treatment of hepatitis c

Country Status (15)

Country	Link
US (2)	US6387365B1 (no)
EP (2)	EP0707855A3 (no)
JP (1)	JPH10506640A (no)
KR (1)	KR19990014925A (no)
CN (1)	CN1190895A (no)
AU (1)	AU5919296A (no)
BR (1)	BR9608758A (no)
CA (1)	CA2221314A1 (no)
CZ (1)	CZ365497A3 (no)
HU (1)	HUP9802324A3 (no)
NO (1)	NO975309L (no)
NZ (1)	NZ309217A (no)
PL (1)	PL323477A1 (no)
SK (1)	SK155997A3 (no)
WO (1)	WO1996036351A1 (no)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE69632062T2 (de)	1995-11-02	2004-11-18	Schering Corp.	Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
US20020137696A1 (en) *	1996-01-23	2002-09-26	Robert Tam	Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes
EP1240899A3 (en) *	1996-01-23	2004-05-19	Ribapharm, Inc.	Modulation of Th1/Th2 Cytokine expression by Ribavirin and Ribavirin analogs in actived T-Lymphocytes for treating HCV infections
PL187439B1 (pl) *	1996-01-23	2004-07-30	Icn Pharmaceuticals	Zastosowanie rybawiryny
AU722987B2 (en) *	1996-02-28	2000-08-17	Unihart Corporation	Pharmaceutical compositions comprising natural human alpha-interferon
AU5157998A (en) *	1996-11-01	1998-05-29	Thomas Najarian	Methods and compositions for treatment of hepatitis c infection
US6172046B1 (en)	1997-09-21	2001-01-09	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US6472373B1 (en)	1997-09-21	2002-10-29	Schering Corporation	Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ES2186660T3 (es) *	1997-09-21	2003-05-16	Schering Corp	Terapia de combinacion para erradicar hcv-rna detectable en pacientes con infeccion por hepatitis c cronica.
PE20000066A1 (es) *	1997-12-22	2000-02-09	Schering Corp	Formas de dosificacion solida de ribavirina administrables oralmente y proceso de fabricacion
AU766597B2 (en) *	1998-05-15	2003-10-16	Schering Corporation	Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having chronic hepatitis C infection
DK1087778T3 (da) *	1998-06-08	2005-12-19	Hoffmann La Roche	Anvendelse af PEG-IFN-alfa og Ribavirin til behandling af kronisk hepatitis C
CA2343522A1 (en) *	1998-09-04	2000-03-16	Viropharma Incorporated	Methods for treating or preventing viral infections and associated diseases
TR200101085T2 (tr) *	1998-10-16	2001-08-21	Schering Corporation	Kronik hepatit C enfeksiyonlu hastalarda algılanabilir HCV-RNA'nın yok edilmesi için birleşik ribavirin-interferon alfa tedavisi
US6403564B1 (en)	1998-10-16	2002-06-11	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
US6277830B1 (en)	1998-10-16	2001-08-21	Schering Corporation	5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
US6824768B2 (en) *	1998-12-18	2004-11-30	Schering Corporation	Ribavirin-pegylated interferon alfa induction HCV combination therapy
WO2000037110A2 (en) *	1998-12-18	2000-06-29	Schering Corporation	Ribavirin-pegylated interferon alfa induction hcv combination therapy
AR022116A1 (es) *	1998-12-18	2002-09-04	Schering Corp	Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
CA2384326A1 (en) *	1999-12-23	2001-06-28	Johnson Lau	Compositions and methods for l-nucleosides, l-nucleotides, and their analogs
EP2213743A1 (en)	2000-04-12	2010-08-04	Human Genome Sciences, Inc.	Albumin fusion proteins
US6924270B2 (en)	2000-04-20	2005-08-02	Schering Corporation	Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CA2417550A1 (en) *	2000-08-02	2002-02-07	Ortho-Mcneil Pharmaceutical, Inc.	Improved anti-viral and anti-tumor chemotherapy by administration of erythropoeitin
US20060024270A1 (en) *	2000-08-23	2006-02-02	The New York Hospital Medical Center Of Queens	Compositions and methods for preventing or treating encephalitis with interferon
AU2001288357A1 (en) *	2000-08-23	2002-03-04	The New York Hospital Medical Center Of Queens	Methods of preventing or treating west nile virus and other infections
AU2002213343A1 (en) *	2000-10-18	2002-04-29	Schering Corporation	Ribavirin-pegylated interferon alfa HCV combination therapy
US6720000B2 (en)	2001-03-19	2004-04-13	Three Rivers Pharmaceutical, Llc	Process for producing wet ribavirin pellets
WO2002097038A2 (en) *	2001-05-25	2002-12-05	Human Genome Sciences, Inc.	Chemokine beta-1 fusion proteins
AU2002346686A1 (en) *	2001-12-07	2003-06-23	Intermune, Inc.	Compositions and method for treating hepatitis virus infection
WO2005003296A2 (en)	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
AU2002364586A1 (en)	2001-12-21	2003-07-30	Delta Biotechnology Limited	Albumin fusion proteins
KR101271635B1 (ko) *	2001-12-21	2013-06-12	휴먼 게놈 사이언시즈, 인코포레이티드	알부민 융합 단백질
CN1665515A (zh)	2002-07-02	2005-09-07	科塞普特治疗公司	治疗与干扰素α治疗相关的精神病的方法
DE60332358D1 (de)	2002-09-09	2010-06-10	Hanall Pharmaceutical Co Ltd	Protease-resistente modifizierte interferon alpha polypeptide
US7538094B2 (en)	2002-09-19	2009-05-26	Three Rivers Pharmacueticals, Llc	Composition containing ribavirin and use thereof
JP2004143113A (ja) *	2002-10-25	2004-05-20	Shinya Nakajima	インターフェロン製剤及びその投与システム
GB0301879D0 (en) *	2003-01-27	2003-02-26	Regent Res Llp	HCV combination therapy
WO2004084796A2 (en) *	2003-03-28	2004-10-07	Pharmasset Ltd.	Compounds for the treatment of flaviviridae infections
CN1852920B (zh)	2003-07-18	2010-12-15	沃泰克斯药物股份有限公司	丝氨酸蛋白酶抑制剂、特别是hcv ns3-ns4a蛋白酶抑制剂
JPWO2006033453A1 (ja) *	2004-09-22	2008-05-15	学校法人順天堂	インターフェロン作用物質の活性増強剤
US7723310B2 (en)	2004-10-18	2010-05-25	Three Rivers Pharmaceuticals, Llc	Large dose ribavirin formulations
US20060159658A1 (en) *	2005-01-19	2006-07-20	Avigenics, Inc.	Methods of treating disease with glycosylated interferon
WO2007013677A1 (ja) *	2005-07-27	2007-02-01	Ajinomoto Co., Inc.	インターフェロン作用物質の活性増強剤
JP2009545621A (ja) *	2006-08-02	2009-12-24	ユナイテッドセラピューティクスコーポレーション	ウィルス感染症のリポソーム処置
KR20090057035A (ko) *	2006-08-21	2009-06-03	유나이티드 세러퓨틱스 코오포레이션	바이러스 감염의 치료를 위한 병용 요법
US20080260820A1 (en) *	2007-04-19	2008-10-23	Gilles Borrelly	Oral dosage formulations of protease-resistant polypeptides
WO2009015336A2 (en) *	2007-07-25	2009-01-29	Biolex Therapeutics, Inc.	Controlled release interferon drug products and treatment of hcv infection using same
KR20100127842A (ko) *	2008-03-26	2010-12-06	유니버시티 오브 옥스퍼드	소포체 표적화 리포좀
CA2737376A1 (en) *	2008-09-17	2010-03-25	Boehringer Ingelheim International Gmbh	Combination of hcv ns3 protease inhibitor with interferon and ribavirin
US8703744B2 (en) *	2009-03-27	2014-04-22	The Chancellor, Masters And Scholars Of The University Of Oxford	Cholesterol level lowering liposomes
EP2459211A1 (en)	2009-07-31	2012-06-06	Medtronic, Inc.	Continuous subcutaneous administration of interferon- to hepatitis c infected patients
EA201200650A1 (ru)	2009-10-30	2012-12-28	Бёрингер Ингельхайм Интернациональ Гмбх	Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
DE202012012955U1 (de)	2011-10-21	2014-07-14	Abbvie Inc.	Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
US8466159B2 (en)	2011-10-21	2013-06-18	Abbvie Inc.	Methods for treating HCV
US8492386B2 (en)	2011-10-21	2013-07-23	Abbvie Inc.	Methods for treating HCV
EP2583677A3 (en)	2011-10-21	2013-07-03	Abbvie Inc.	Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
WO2013116592A1 (en) *	2012-02-01	2013-08-08	Kadmon Pharmaceuticals, Llc	Once daily treatment of hepatitis c with ribavirin and taribavirin
EA201892448A1 (ru)	2016-04-28	2019-06-28	Эмори Юниверсити	Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211771A (en)	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
USRE29835E (en)	1971-06-01	1978-11-14	Icn Pharmaceuticals	1,2,4-Triazole nucleosides
US4530901A (en)	1980-01-08	1985-07-23	Biogen N.V.	Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5676942A (en) *	1992-02-10	1997-10-14	Interferon Sciences, Inc.	Composition containing human alpha interferon species proteins and method for use thereof

1995
- 1995-05-19 US US08/444,584 patent/US6387365B1/en not_active Expired - Lifetime
- 1995-12-28 EP EP95309499A patent/EP0707855A3/en not_active Ceased
- 1995-12-28 EP EP99123925A patent/EP1005868A1/en not_active Withdrawn
1996
- 1996-05-15 CN CN96195591A patent/CN1190895A/zh active Pending
- 1996-05-15 KR KR1019970708271A patent/KR19990014925A/ko not_active Ceased
- 1996-05-15 BR BR9608758A patent/BR9608758A/pt not_active Application Discontinuation
- 1996-05-15 CZ CZ973654A patent/CZ365497A3/cs unknown
- 1996-05-15 HU HU9802324A patent/HUP9802324A3/hu unknown
- 1996-05-15 PL PL96323477A patent/PL323477A1/xx unknown
- 1996-05-15 WO PCT/US1996/006552 patent/WO1996036351A1/en not_active Ceased
- 1996-05-15 NZ NZ309217A patent/NZ309217A/xx unknown
- 1996-05-15 AU AU59192/96A patent/AU5919296A/en not_active Abandoned
- 1996-05-15 JP JP8534904A patent/JPH10506640A/ja active Pending
- 1996-05-15 CA CA002221314A patent/CA2221314A1/en not_active Abandoned
- 1996-05-15 SK SK1559-97A patent/SK155997A3/sk unknown
1997
- 1997-11-19 NO NO975309A patent/NO975309L/no not_active Application Discontinuation
2000
- 2000-05-02 US US09/563,649 patent/US6299872B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US6299872B1 (en)	2001-10-09
EP0707855A2 (en)	1996-04-24
WO1996036351A1 (en)	1996-11-21
PL323477A1 (en)	1998-03-30
US6387365B1 (en)	2002-05-14
NZ309217A (en)	2000-08-25
HUP9802324A3 (en)	2001-04-28
EP1005868A1 (en)	2000-06-07
AU5919296A (en)	1996-11-29
CA2221314A1 (en)	1996-11-21
BR9608758A (pt)	1999-07-06
JPH10506640A (ja)	1998-06-30
EP0707855A3 (en)	1996-11-27
NO975309D0 (no)	1997-11-19
MX9708885A (es)	1998-03-31
NO975309L (no)	1997-11-19
HUP9802324A2 (hu)	1999-05-28
CZ365497A3 (cs)	1998-07-15
KR19990014925A (ko)	1999-02-25
CN1190895A (zh)	1998-08-19

Publication	Publication Date	Title
SK155997A3 (en)	1998-10-07	Use of ribavirin and interferon alpha for the treatment of hepatitis c
US20050112093A1 (en)	2005-05-26	Combination therapy for HCV infection
KR20050055053A (ko)	2005-06-10	만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도
US20070202078A1 (en)	2007-08-30	Method Of Treating Viral Infections
RU2002105485A (ru)	2004-01-27	Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α)
JP2007501806A5 (no)	2007-09-20
US20090035273A1 (en)	2009-02-05	Combination treatment method with interferon-tau
HK1008811A (en)	1999-05-21	Combination therapy for chronic hepatitis c infection
JP5034944B2 (ja)	2012-09-26	インターフェロン作用物質の活性増強剤
MXPA97008885A (en)	1998-10-15	Use of ribavirin and interferon alpha for the treatment of hepatiti
Pellicano et al.	2002	Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection
WO2008021536A2 (en)	2008-02-21	Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects
KR20140007927A (ko)	2014-01-20	C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르
Simsek et al.	1996	Treatment of Chronic Hepatitis C Infection with Interferon α-2 a in a Turkish Population
JP2004155777A (ja)	2004-06-03	Ｃ型慢性肝炎治療剤
MXPA06001695A (en)	2006-10-17	Method of treating viral infections
Jeffries et al.	0	Quantitative PCR< IO00 cp/m! at treatment week 24 Group1 (n= 78) Group 2 (n= 74) Total (n= 152)
KR20140011379A (ko)	2014-01-28	알리스포리비르를 사용하는 c형 간염 바이러스 감염의 치료